|
| |
Image Results
Loading...
Loading...
TARCEVA Pages on BioPortfolio:
|
BioPortfolio - Tarceva
Panel Votes Against Approval of Tarceva(R) as Maintenance Drug WASHINGTON, Dec. 17 /PRNewswire-USNewswire/ -- Yesterday, an advisory committee to the Food ...
http://www.bioportfolio.com/indepth/Tarceva.html...
|
Biotechnology News TAXOTERE Search
WASHINGTON -- Federal health regulators say OSI Pharmaceutical's Tarceva slows the progression of lung cancer and extends patients' lives when used as a ...
http://www.bioportfolio.co.uk/TAXOTERE-news.htm...
|
BioPortfolio - OSI Pharmaceuticals - Profile
UPDATE 1-OSI Pharma says FDA extends Tarceva review ... OSI Pharma, Genentech Say FDA Extends Review Period Of Tarceva SNDA For Use In Lung Cancer - ...
http://www.bioportfolio.com/biocorporate/7940-OSI%2525252525...
|
Biotechnology News patent Search
OSI Pharmaceuticals, Inc announced that the US Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's (erlotinib) ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?DB=ne...
|
The Board of International Biotechnology Trust Plc (“IBT”) today ...
In mid-November 2004, OSI Pharmaceuticals and partner Genentech announced the approval of OSIs lead drug Tarceva to treat non-small cell carcinoma (NSCLC).
...
http://www.bioportfolio.com/news/International_Biotechnology...
|
BioPortfolio.com - BioWeb OMNITROPE SOMATROPIN RECOMBINANT isrupt ...
Home Contact Us Site Index Search [ Products -- Nutropin ] Products Home ONCOLOGY Avastin Herceptin Rituxan Tarceva IMMUNOLOGY Raptiva Xolair VASCULAR
...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?DB=se...
|
Cyclacel (NASDAQ:CYCC) appoints Nicholas Bacopoulos, Ph.D. to ...
He was previously President and Head of R&D at OSI Pharmaceuticals, where he was involved with the global development of Tarceva®, approved for the ...
http://www.bioportfolio.com/biotech_news/Cyclacel_Pharmaceut...
| Results from other life science and pharmaceutical sites:
Genentech: Medicines: Tarceva
Tarceva is a selective and orally active inhibitor of the Epidermal Growth Factor Receptor (EGFR), tyrosine kinase, that is associated with the aberrant
...
http://www.gene.com/gene/products/information/oncology/tarce...
|
Erlotinib - Wikipedia, the free encyclopedia
Erlotinib hydrochloride (Tarceva) is a drug used to treat non-small cell lung .... Tarceva has been shown to extend the lives of some cancer patients and to
...
http://en.wikipedia.org/wiki/Erlotinib...
|
Genentech: Medicines: Tarceva Fact Sheet
Skip to Content for Tarceva Fact Sheet Menu for Tarceva Fact Sheet About Us Menu Research Menu Development Menu Medicines Menu Investors Menu Media Menu ...
http://www.gene.com/gene/products/information/oncology/tarce...
|
FINAL 30April 2009 PI-Clean
TARCEVA safely and effectively. See full prescribing information for .... showed no clinical benefit with the concurrent administration of TARCEVA with ...
http://www.osip.com/full_PI_tarceva...
|
Genentech: Investors: Tarceva - Historical Sales
Skip to Content for Tarceva - Historical Sales Menu for Tarceva - Historical Sales About Us Menu Research Menu Development Menu Medicines Menu Investors ...
http://www.gene.com/gene/ir/financials/historical/tarceva.ht...
|
Roche - Tarceva (Erlotinib)
Skip over Breadcrumb. You are here: Products: > Tarceva (Erlotinib). Tarceva ( Erlotinib). For the treatment of patients with lung and pancreatic cancer. ...
http://www.roche.com/products/product-details.htm?type=produ...
|
Tarceva template
18 Nov 2004 ... To review data supporting the need for new treatment options for patients with pancreatic cancer; To present evidence that Tarceva, ...
http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4174S1_05...
|
Roche - New cancer drug Tarceva - a breakthrough with significant ...
26 Apr 2004 ... Roche, Genentech, Inc. and OSI Pharmaceuticals, Inc., today announced positive results from a phase III study of Tarceva (erlotinib) in ...
http://www.roche.com/med-cor-2004-04-26b...
|
Tarceva (erlotinib) May 2009
8 May 2009 ... Dear Healthcare Professional letter issued to warn about GI perforation, exfoliative skin conditions and corneal perforation/ulceration.
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyA...
|
Overcoming acquired resistance to Iressa/Tarceva with inhibitors ...
However, the remissions induced by these drugs (Iressa and Tarceva) are typically short-lived, presumably due to acquired drug resistance. ...
http://www.ncbi.nlm.nih.gov/pubmed/15970680...
|
|
